statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three months ended March 31, 2024, and provided operating and partner program updates. The OmniAb team continued to make great...

OmniAb Reports First Quarter 2024 Financial Results and Business Highlights

OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating in five investor conferences during the month of May. RBC Capital Markets Global Healthcare Conference, May 14-15 at...

OmniAb to Participate in Five Investor Conferences in May

OmniAb, Inc. (NASDAQ: OABI) will report financial results for the three months ended March 31, 2024 after the close of the U.S. financial markets on Thursday, May 9, 2024 and will hold a conference...

OmniAb to Report First Quarter 2024 Financial Results on May 9

OmniAb, Inc. (NASDAQ:OABI  Free Report)  Research analysts at HC Wainwright cut their FY2024 EPS estimates for shares of OmniAb in a note issued to investors on Thursday, March 21st...

Research Analysts Set Expectations for OmniAb, Inc.'s FY2024 Earnings (NASDAQ:OABI)

OmniAb Inc (OABI) President and CEO Matthew Foehr Acquires 225,000 Shares

Q4 2023 OmniAb Inc Earnings Call Transcript

Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on OmniAb (OABI Research Report). The associated price target is $11...

OmniAb's Market Potential and Financial Stability Affirm Buy Rating

Revenue Drops Amidst Expansion Efforts and Increased R&D SpendingRelated Stocks: OABI...

OmniAb Inc (OABI) Reports Decline in Annual Revenue and Net Loss for Q4 and Full Year 2023

Recap: OmniAb Q4 Earnings

OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and 12 months ended December 31, 2023, and provided operating and partner program updates. 2023 was a year of significant...

OmniAb Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

OmniAb, Inc. operates as a drug discovery company. It focuses on developing human monoclonal and bispecific therapeutic antibodies. Its platform includes the biological intelligence of its transgenic animals, including OmniRat, OmniChicken and OmniMouse. The company was founded on December 14, 2015 and is headquartered in Emeryville, CA.

Watchers	206
52-Wk Low	$3.50
52-Wk High	$6.72

Volume	1.15M
52-Wk High	$6.72
52-Wk Low	$3.50

OABI OmniAb Inc

About

Feed

News

Sentiment

Fundamentals